Information Provided By:
Fly News Breaks for December 15, 2017
Dec 15, 2017 | 07:14 EDT
Cantor Fitzgerald analyst Elemer Piros last night initiated Rigel Pharmaceuticals with an Overweight rating and $6 price target. The company is poised to achieve FDA approval of fostamatinib for lead indication immune thrombocytopenia, Piros tells investors in a research note. The analyst also believes fostamatinib has an attractive opportunity to expand its use with additional immune-related rare conditions autoimmune hemolytic anemia and immunoglobulin A nephropathy, both of which are in Phase 2 development.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.